JAK1 and graft versus host disease: An ongoing study assessing JAK1 selective inhibition with itacitinib for prophylaxis of GVHD and CRS in haplo-HSCT utilized itacitinib at doses of 200 mg/day on days -3 through +100 in combination with tacrolimus, MMF, and PTCy.